EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 748 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Embrace Your Inner Flexibility March 29, 2021 Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition... July 27, 2021 Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... October 4, 2021 Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line... December 22, 2021 Load more HOT NEWS NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures... Combination Therapy for Metastatic Prostate Cancer Helps Some Men Live Longer World Cancer Research Day: Celebrating Progress in Treating and Caring for...
